Relapsing polychondritis
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ,Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2]
Overview
Relapsing polychondritis is an immune-mediated chronic disease which involves the cartilaginous structure of different parts of the body, most commonly those of the ears, nose, and laryngotracheobronchial tree. The term relapsing polychondritis was first coined by Pearson in 1960. The majority of patients with relapsing polychondritis remain asymptomatic for several years. Early clinical features include ear pain, polyarthritis and other non-specific symptoms such as fever, weight loss and skin rash. The pathogenesis of relapsing polychondritis is unknown, however several studies have suggested the role of both cellular immunity and abnormal autoantibody in the pathogenesis of relapsing polychondritis. There are two different criteria to diagnose relapsing polychondritis which include Mc Adam criteria and modified Damiani criteria. There are no specific laboratory findings associated with relapsing polychondritis but certain antibodies are raised such as anti-type II collagen antibodies and antineutrophil cytoplasmic antibodies. Other abnormal laboratory findings include low haemoglobin, leukocytosis, eosinophilia, increased ESR, CRP, urinary glycosaminoglycans levels and urinary collagen type II neoepitope levels in active inflammation. Imaging such as chest x-ray is helpful to find out tracheal stenosis, however, CT scan is more useful to diagnose subglottic stenosis. MRI is useful to see the difference between edema, fibrosis, and inflammation. The mainstay of therapy for relapsing polychondritis is medical therapy. NSAIDs are used as an initial treatment of relapsing polychondritis. If NSAIDs are contraindicated or resistant, then steroids or dapsone can be used. Prednisone is used in the treatment of relapse. Treatment of life-threatening organ damage include prednisone and cyclophosphamide. Various surgical options include tracheostomy, cardiac valve replacement, aortic aneurysm repair, and saddle-nose deformity repair.
Historical Perspective
- In 1923, Jaksch-Wartenhorst used the term polychondropathia to describe his first case about relapsing polychondritis.
- In 1960, the term relapsing polychondritis was first coined by Pearson.
Classification
- There is no established classification of relapsing polychondritis.
Pathophysiology
- The pathogenesis of relapsing polychondritis is unknown.
- Several studies have suggested the role of both cellular immunity and abnormal autoantibody in the pathogenesis of relapsing polychondritis.
- The HLA class II has been associated with the development of relapsing polychondritis, there is increase susceptibility with HLA-DR4.[1]
- On gross pathology, thickening of cartilage of ear, nose, epiglottis, and cricoid and tracheal rings are characteristic findings of relapsing polychondritis.
- On microscopic histopathological analysis of relapsing polychondritis, following features are seen:
- Lymphocytes, plasma cells, neutrophils, and eosinophils are seen in the cartilage.
- Cartilage has lost the chondrocytes and normal architecture at the later stages of inflammation.
- Cartilage is replaced by fibrous tissue in the end.
Differentiating Relapsing Polychondritis from other Diseases
- Chondritis
- Chondromdermatitis
- Hansen's disease
- Nodularis helicis
- Perichondritis
- Rhinophyma
- Skin cancer
- Syphilis
Also, Relapsing Polychondritis should be differenttieted form other causes of small-sized vessel vasculitis. Abbreviations: ABG= Arterial blood gas, ANA= Antinuclear antibody, ANP= Atrial natriuretic peptide, ASO= Antistreptolysin O antibody, BNP= Brain natriuretic peptide, CBC= Complete blood count, COPD= Chronic obstructive pulmonary disease, CRP= C-reactive protein, CT= Computed tomography, CXR= Chest X-ray, DVT= Deep vein thrombosis, ESR= Erythrocyte sedimentation rate, HRCT= High Resolution CT, IgE= Immunoglobulin E, LDH= Lactate dehydrogenase, PCWP= Pulmonary capillary wedge pressure, PCR= Polymerase chain reaction, PFT= Pulmonary function test.
Epidemiology and Demographics
- The incidence of relapsing polychondritis is approximately 4 per 100,000 individuals in Minnesota.
Age
- Relapsing polychondritis is more commonly observed among patients aged 40 to 60 years but it can also occur in childhood.[32][33]
Gender
- Relapsing polychondritis affects men and women equally.
Race
- Relapsing polychondritis usually affects Caucasian.
Risk Factors
Common risk factors in the development of relapsing polychondritis include:
- Genetic susceptibility:
- Increased risk with HLA DR4
- History of other connective tissue disorders
Natural History, Complications and Prognosis
- The majority of patients with relapsing polychondritis remain asymptomatic for several years.
- Early clinical features include ear pain, polyarthritis and other non-specific symptoms such as fever, weight loss and skin rash.
- Common complications of relapsing polychondritis include collapsing of cartilage which causes facial abnormalities, deformities of the ear, eye, and destruction of the thyroid gland.
- Relapsing polychondritis has the relapsing and remitting course, Prognosis depends upon the type of organ involvement, stage of the disease.
Diagnosis
Diagnostic Criteria
Mc Adam diagnostic criteria for relapsing polychondritis[34] | |
---|---|
Criteria | Requirement |
Recurrent chondritis of both auricles | 3 out of 6 features
are required for definitive diagnosis of relapsing polychondritis |
Non-erosive inflammatory polyarthritis | |
Nasal chondritis | |
Inflammation of auricular structures | |
Chondritis of the respiratory tract | |
Cochlear and/or vestibular damage |
According to modified Damiani criteria, there should be one of the following findings to diagnose relapsing polychondritis:[35]
- There should be three of McAdam's diagnostic criteria.
- One or more of the clinical findings of McAdam's diagnostic criteria and positive histologic confirmation.
- Chondritis at two or more separate anatomic locations with a response to glucocorticoids or dapsone.
Symptoms
Symptoms of relapsing polychondritis may include the following:[36][37][38][39]
- Ear pain
- Eye pain, redness, and increased lacrimation
- Decreased visual acuity
- Proptosis
- Rhinorrhea
- Epistaxis
- Pain on the movement of joint
- Joint swelling
- Cough
- Shortness of breath
- Dysphagia
- Chest pain
- Headache
- Confusion
Physical Examination
- Patients with relapsing polychondritis usually appear lethargic.
- Physical examination may be remarkable for:
- Ear examination:
- On inspection, there is inflammation and swelling
- On palpation, there is tenderness
- Eye examination:
- On inspection, lid retraction, redness of the eye, ptosis, and proptosis
- Visual acuity is decreased
- Lung examination:
- Heart examination:
- S1, S2 is normal, the murmur can be heard depending on the involvement of valve
- Joint examination:
- On inspection, there is redness and swelling
- On palpation, there is tenderness
Laboratory Findings
- There are no specific laboratory findings associated with relapsing polychondritis.
- Abnormal laboratory findings consistent with the diagnosis of relapsing polychondritis include:
- CBC with differentials
- ESR and CRP are usually raised
- Antibody testing
- Anti-type II collagen antibodies is usually raised in early phase of disease[40][41]
- Antineutrophil cytoplasmic antibodies is found in patients who has vasculitis[42]
- Urinary glycosaminoglycans levels may be elevated
- Urinary collagen type II neoepitope levels is elevated in active inflammation[43]
- Levels of urinary collagen type II neoepitope is used to assess response to treatment[44]
- Serum levels of cartilage oligomeric matrix protein is elevated and used as a marker of disease activity[45]
Imaging Findings
- X-ray of the chest shows tracheal stenosis.
- CT scan of the chest shows following findings:[46]
- Subglottic stenosis
- Thickening of anterior and lateral tracheal wall with sparing of the posterior membranous wall
- MRI is better than CT scanning to see the difference between edema, fibrosis, and inflammation
Other Diagnostic studies
- ECG and Echocardiography are done in the patient who has cardiac involvement.
- Bronchoscopy used to visualize extensive disease involving the lungs.
Treatment
Medical Therapy
- The mainstay of therapy for relapsing polychondritis is medical therapy.
- NSAIDs are used as an initial treatment of relapsing polychondritis.[49]
- Preferred regimen: Naproxen 500 mg PO q12h or ibuprofen 800 mg PO q6h x 7 to 10 days.
- If NSAIDs are contraindicated or resistant then following regimens are used:
- Preferred regimen: Dapsone 50 to 100 mg PO q24h x 4 months depending on the severity of the disease.
- Preferred regimen: Prednisone 30 to 60 mg PO q24h in divided dose.
Treatment of relapse:
- Preferred regimen: Prednisone 5 to 7.5 mg PO q24h
Treatment of life-threatening organ damage:
- Preferred regimen: Initial therapy is the combination of prednisone 1 mg/kg PO q24h and cyclophosphamide 2 mg/kg PO q24h.
- Maintenance therapy depends on the renal function of a patient.
- Patient without nephritis, Preferred regimen: Methotrexate 15mg PO once weekly.
- Patient with nephritis, Preferred regimen: Azathioprine - dose is adjused according to GFR.
Surgery
Medical therapy is the mainstay of therapy for relapsing polychondritis, however various surgical options include:
- Tracheostomy
- Cardiac valve replacement
- Aortic aneurysm repair
- Saddle-nose deformity repair
Prevention
There are no primary preventive measures available for relapsing polychondritis.
References
- ↑ Lang B, Rothenfusser A, Lanchbury JS, Rauh G, Breedveld FC, Urlacher A, Albert ED, Peter HH, Melchers I (May 1993). "Susceptibility to relapsing polychondritis is associated with HLA-DR4". Arthritis Rheum. 36 (5): 660–4. PMID 8489544.
- ↑ Chung SA, Seo P (2010). "Microscopic polyangiitis". Rheum Dis Clin North Am. 36 (3): 545–58. doi:10.1016/j.rdc.2010.04.003. PMC 2917831. PMID 20688249.
- ↑ Kubaisi B, Abu Samra K, Foster CS (2016). "Granulomatosis with polyangiitis (Wegener's disease): An updated review of ocular disease manifestations". Intractable Rare Dis Res. 5 (2): 61–9. doi:10.5582/irdr.2016.01014. PMC 4869584. PMID 27195187.
- ↑ Keogh KA, Specks U (April 2006). "Churg-Strauss syndrome". Semin Respir Crit Care Med. 27 (2): 148–57. doi:10.1055/s-2006-939518. PMID 16612766.
- ↑ Keasberry J, Frazier J, Isbel NM, Van Eps CL, Oliver K, Mudge DW (2013). "Hydralazine-induced anti-neutrophil cytoplasmic antibody-positive renal vasculitis presenting with a vasculitic syndrome, acute nephritis and a puzzling skin rash: a case report". J Med Case Rep. 7: 20. doi:10.1186/1752-1947-7-20. PMC 3565908. PMID 23316942.
- ↑ McAdoo SP, Pusey CD (July 2017). "Anti-Glomerular Basement Membrane Disease". Clin J Am Soc Nephrol. 12 (7): 1162–1172. doi:10.2215/CJN.01380217. PMID 28515156.
- ↑ Ferri C, Mascia MT (January 2006). "Cryoglobulinemic vasculitis". Curr Opin Rheumatol. 18 (1): 54–63. PMID 16344620.
- ↑ Guo QY, Wu M, Wang YW, Sun GD (2017). "Hepatitis C virus-associated cryoglobulinemia with membrano-proliferative glomerulonephritis treated with prednisolone and interferon: A case report". Exp Ther Med. 14 (2): 1395–1398. doi:10.3892/etm.2017.4671. PMC 5525644. PMID 28810602.
- ↑ Farhadian JA, Castilla C, Shvartsbeyn M, Meehan SA, Neimann A, Pomeranz MK (December 2015). "IgA vasculitis (Henoch-Schönlein purpura)". Dermatol. Online J. 21 (12). PMID 26990342.
- ↑ Buck A, Christensen J, McCarty M (2012). "Hypocomplementemic urticarial vasculitis syndrome: a case report and literature review". J Clin Aesthet Dermatol. 5 (1): 36–46. PMC 3277093. PMID 22328958.
- ↑ Sise MJ (February 2014). "Acute mesenteric ischemia". Surg. Clin. North Am. 94 (1): 165–81. doi:10.1016/j.suc.2013.10.012. PMID 24267504.
- ↑ McDonald JR (2009). "Acute infective endocarditis". Infect Dis Clin North Am. 23 (3): 643–64. doi:10.1016/j.idc.2009.04.013. PMC 2726828. PMID 19665088.
- ↑ Einhorn J, Levis JT (2015). "Dermatologic Diagnosis: Leukocytoclastic Vasculitis". Perm J. 19 (3): 77–8. doi:10.7812/TPP/15-001. PMC 4500485. PMID 26176572.
- ↑ Margo CE, Goldman DR (2008). "Langerhans cell histiocytosis". Surv Ophthalmol. 53 (4): 332–58. doi:10.1016/j.survophthal.2008.04.007. PMID 18572052.
- ↑ Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008). "Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship". Mayo Clin Proc. 83 (5): 584–94. doi:10.4065/83.5.584. PMC 2718421. PMID 18452692.
- ↑ Jackman DM, Johnson BE (2005). "Small-cell lung cancer". Lancet. 366 (9494): 1385–96. doi:10.1016/S0140-6736(05)67569-1. PMID 16226617.
- ↑ Parambil JG, Savci CD, Tazelaar HD, Ryu JH (April 2005). "Causes and presenting features of pulmonary infarctions in 43 cases identified by surgical lung biopsy". Chest. 127 (4): 1178–83. doi:10.1378/chest.127.4.1178. PMID 15821192.
- ↑ VanDeVoorde RG (January 2015). "Acute poststreptococcal glomerulonephritis: the most common acute glomerulonephritis". Pediatr Rev. 36 (1): 3–12, quiz 13. doi:10.1542/pir.36-1-3. PMID 25554106.
- ↑ Corrigan JJ, Boineau FG (November 2001). "Hemolytic-uremic syndrome". Pediatr Rev. 22 (11): 365–9. PMID 11691946.
- ↑ Byrd JC, Stilgenbauer S, Flinn IW (2004). "Chronic lymphocytic leukemia". Hematology Am Soc Hematol Educ Program: 163–83. doi:10.1182/asheducation-2004.1.163. PMID 15561682.
- ↑ Michels TC, Petersen KE (March 2017). "Multiple Myeloma: Diagnosis and Treatment". Am Fam Physician. 95 (6): 373–383. PMID 28318212.
- ↑ Klion A (2009). "Hypereosinophilic syndrome: current approach to diagnosis and treatment". Annu. Rev. Med. 60: 293–306. doi:10.1146/annurev.med.60.062107.090340. PMID 19630574.
- ↑ Shankland KR, Armitage JO, Hancock BW (September 2012). "Non-Hodgkin lymphoma". Lancet. 380 (9844): 848–57. doi:10.1016/S0140-6736(12)60605-9. PMID 22835603.
- ↑ Lin RY (January 1986). "Serum sickness syndrome". Am Fam Physician. 33 (1): 157–62. PMID 2867672.
- ↑ Venugopal A (2014). "Disseminated intravascular coagulation". Indian J Anaesth. 58 (5): 603–8. doi:10.4103/0019-5049.144666. PMC 4260307. PMID 25535423.
- ↑ Nomura S (2016). "Advances in Diagnosis and Treatments for Immune Thrombocytopenia". Clin Med Insights Blood Disord. 9: 15–22. doi:10.4137/CMBD.S39643. PMC 4948655. PMID 27441004.
- ↑ Chiarchiaro J, Chen BB, Gibson KF (2016). "New molecular targets for the treatment of sarcoidosis". Curr Opin Pulm Med. 22 (5): 515–21. doi:10.1097/MCP.0000000000000304. PMC 5152532. PMID 27454074.
- ↑ Murdoch DR (January 2003). "Diagnosis of Legionella infection". Clin. Infect. Dis. 36 (1): 64–9. doi:10.1086/345529. PMID 12491204.
- ↑ Tsokos, George C. (2011). "Systemic Lupus Erythematosus". New England Journal of Medicine. 365 (22): 2110–2121. doi:10.1056/NEJMra1100359. ISSN 0028-4793.
- ↑ Scott JT (1991). "The gold standard in rheumatoid arthritis". J R Soc Med. 84 (9): 513–4. PMC 1293405. PMID 1682491.
- ↑ Emmungil H, Aydın SZ (2015). "Relapsing polychondritis". Eur J Rheumatol. 2 (4): 155–159. doi:10.5152/eurjrheum.2015.0036. PMC 5047229. PMID 27708954.
- ↑ Knipp S, Bier H, Horneff G, Specker C, Schuster A, Schroten H, Lenard HG, Niehues T (2000). "Relapsing polychondritis in childhood--case report and short review". Rheumatol. Int. 19 (6): 231–4. PMID 11063294.
- ↑ Belot A, Duquesne A, Job-Deslandre C, Costedoat-Chalumeau N, Boudjemaa S, Wechsler B, Cochat P, Piette JC, Cimaz R (March 2010). "Pediatric-onset relapsing polychondritis: case series and systematic review". J. Pediatr. 156 (3): 484–9. doi:10.1016/j.jpeds.2009.09.045. PMID 19880136.
- ↑ McAdam LP, O'Hanlan MA, Bluestone R, Pearson CM (May 1976). "Relapsing polychondritis: prospective study of 23 patients and a review of the literature". Medicine (Baltimore). 55 (3): 193–215. PMID 775252.
- ↑ Damiani JM, Levine HL (June 1979). "Relapsing polychondritis--report of ten cases". Laryngoscope. 89 (6 Pt 1): 929–46. PMID 449538.
- ↑ Coppola M, Yealy DM (January 1992). "Relapsing polychondritis: an unusual cause of painful auricular swelling". Ann Emerg Med. 21 (1): 81–5. PMID 1539895.
- ↑ Kent PD, Michet CJ, Luthra HS (January 2004). "Relapsing polychondritis". Curr Opin Rheumatol. 16 (1): 56–61. PMID 14673390.
- ↑ O'Hanlan M, McAdam LP, Bluestone R, Pearson CM (1976). "The arthropathy of relapsing polychrondritis". Arthritis Rheum. 19 (2): 191–4. PMID 1259793.
- ↑ Balsa A, Expinosa A, Cuesta M, MacLeod TI, Gijón-Baños J, Maddison PJ (1995). "Joint symptoms in relapsing polychondritis". Clin. Exp. Rheumatol. 13 (4): 425–30. PMID 7586772.
- ↑ Foidart JM, Abe S, Martin GR, Zizic TM, Barnett EV, Lawley TJ, Katz SI (November 1978). "Antibodies to type II collagen in relapsing polychondritis". N. Engl. J. Med. 299 (22): 1203–7. doi:10.1056/NEJM197811302992202. PMID 714080.
- ↑ Ebringer R, Rook G, Swana GT, Bottazzo GF, Doniach D (October 1981). "Autoantibodies to cartilage and type II collagen in relapsing polychondritis and other rheumatic diseases". Ann. Rheum. Dis. 40 (5): 473–9. PMC 1000784. PMID 7030234.
- ↑ Papo T, Piette JC, Le Thi Huong D, Godeau P, Meyer O, Kahn MF, Bourgeois P (May 1993). "Antineutrophil cytoplasmic antibodies in polychondritis". Ann. Rheum. Dis. 52 (5): 384–5. PMC 1005055. PMID 8323388. Vancouver style error: initials (help)
- ↑ Passos CO, Onofre GR, Martins RC, Graff DL, Pagani EA, Sodré CT, Silva LC (July 2002). "Composition of urinary glycosaminoglycans in a patient with relapsing polychondritis". Clin. Biochem. 35 (5): 377–81. PMID 12270767.
- ↑ Kraus VB, Stabler T, Le ET, Saltarelli M, Allen NB (October 2003). "Urinary type II collagen neoepitope as an outcome measure for relapsing polychondritis". Arthritis Rheum. 48 (10): 2942–8. doi:10.1002/art.11281. PMID 14558101.
- ↑ Kempta Lekpa F, Piette JC, Bastuji-Garin S, Kraus VB, Stabler TV, Poole AR, Marini-Portugal A, Chevalier X (2010). "Serum cartilage oligomeric matrix protein (COMP) level is a marker of disease activity in relapsing polychondritis". Clin. Exp. Rheumatol. 28 (4): 553–5. PMID 20810035.
- ↑ Lee KS, Ernst A, Trentham DE, Lunn W, Feller-Kopman DJ, Boiselle PM (August 2006). "Relapsing polychondritis: prevalence of expiratory CT airway abnormalities". Radiology. 240 (2): 565–73. doi:10.1148/radiol.2401050562. PMID 16801364.
- ↑ href="https://radiopaedia.org/">Radiopaedia.org
- ↑ href="https://radiopaedia.org/cases/31793">rID: 31793
- ↑ Yoo JH, Chodosh J, Dana R (2011). "Relapsing polychondritis: systemic and ocular manifestations, differential diagnosis, management, and prognosis". Semin Ophthalmol. 26 (4–5): 261–9. doi:10.3109/08820538.2011.588653. PMID 21958172.
External links
- Polychondritis Educational Society, Ltd. (PES)
- Dr. D. E. Trentham research paper
- MedicineNet.com
- The Polychondritis Group - Support Group
Template:Osteochondropathy
Template:Diseases of the musculoskeletal system and connective tissue